Pharma Capital

Legal & General ups stake in ImmuPharma

L&G upped its stake in the recent £4.1mln fundraising, and now holds a 3.5% stake in ImmuPharma
Legal & General offices
Analysts said L&G's increased stake was indicative of the interest now being shown in ImmuPharma from institutions

Insurance giant Legal & General Group Plc (LON:LGEN) has upped its stake in the AIM-listed specialist drug developer ImmuPharma PLC (LON:IMM).

L&G upped its stake in the recent £4.1mln fundraising, and now holds 4.45mln ImmuPharma shares representing 3.5% of the issued share capital.

“We are delighted to be able to disclose Legal & General's increased holding in ImmuPharma as one of our existing major institutional investors which participated in our recent successful £4.1 million fundraising demonstrating its continued support for ImmuPharma,” said chief executive Tim McCarthy.

City broker Northland Capital said L&G taking a larger piece of the pie was indicative of the kind of interest ImmuPharma is now generating among institutional investors.

“The announcement that L&G increased its stake in ImmuPharma demonstrates the strong interest in the company’s late-stage clinical drug development programme on Lupuzor, a potential treatment for Lupus,” said Northland analyst Vadim Alexandre.

“If approved, Lupuzor could achieve multi-billion dollar annual sales.”

Shares in ImmuPharma were modestly lower at 53.5p on Monday afternoon.

View full IMM profile

ImmuPharma PLC Timeline

View All

Related Articles

picture of drug research
“The positive results from this feasibility award may lead to other opportunities to secure additional funding awards to advance the programme further," Dr John Reader, Sareum's chief scientific officer said.

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.